Bavarian Nordic v. Acambis, PLC (Inv. No. 337-TA-550)
Bavarian Nordic A/S filed a Section 337 action against Acambis, PLC alleging that Acambis misappropriated proprietary technology used in the development and production of a third-generation smallpox vaccine. Specifically, Bavarian Nordic alleged that Acambis unlawfully obtained access to virus materials and trade secrets owned by Bavarian Nordic and used them to compete for U.S. government contracts relating to the establishment of a strategic stockpile of new smallpox vaccine.
Managing Principal John Jarosz submitted an expert report and provided deposition testimony on the existence of a domestic industry relating to the technology at issue, as well as the harm suffered by that industry. Vice Presidents Michael Chapman and Robin Heider supported Mr. Jarosz.
The case settled before trial.